Why is Haemonetics Corp. ?
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.96
2
Poor long term growth as Net Sales has grown by an annual rate of 7.32% and Operating profit at 8.03% over the last 5 years
3
Flat results in Jun 25
- DEBT-EQUITY RATIO (HY) Highest at 105.62 %
- INTEREST(Q) At USD 4.07 MM has Grown at inf%
- INVENTORY TURNOVER RATIO(HY) Lowest at 1.69 times
4
With ROCE of 12.30%, it has a attractive valuation with a 2.47 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 1.33%, its profits have risen by 1.5% ; the PEG ratio of the company is 8.4
5
Underperformed the market in the last 1 year
- The stock has generated a return of 1.33% in the last 1 year, much lower than market (S&P 500) returns of 14.11%
How much should you hold?
- Overall Portfolio exposure to Haemonetics Corp. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Haemonetics Corp. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Haemonetics Corp.
-8.94%
-0.03
53.55%
S&P 500
16.41%
0.70
20.15%
Quality key factors
Factor
Value
Sales Growth (5y)
8.32%
EBIT Growth (5y)
15.08%
EBIT to Interest (avg)
8.96
Debt to EBITDA (avg)
2.49
Net Debt to Equity (avg)
1.13
Sales to Capital Employed (avg)
0.67
Tax Ratio
20.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.56%
ROE (avg)
14.77%
Valuation Key Factors 
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
3.04
EV to EBIT
14.93
EV to EBITDA
10.21
EV to Capital Employed
2.05
EV to Sales
2.76
PEG Ratio
0.57
Dividend Yield
NA
ROCE (Latest)
13.73%
ROE (Latest)
19.13%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Mildly Bullish
Technical Movement
9What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 338.84 MM
ROCE(HY)
Highest at 19.3%
RAW MATERIAL COST(Y)
Fallen by -6.9% (YoY
CASH AND EQV(HY)
Highest at USD 659.79 MM
OPERATING PROFIT(Q)
Highest at USD 96.95 MM
PRE-TAX PROFIT(Q)
Highest at USD 61.44 MM
NET PROFIT(Q)
Highest at USD 45.83 MM
-3What is not working for the Company
INTEREST(Q)
At USD 8.12 MM has Grown at 12.62%
DEBTORS TURNOVER RATIO(HY)
Lowest at 6.47 times
Here's what is working for Haemonetics Corp.
Operating Cash Flow
Highest at USD 338.84 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Operating Profit
Highest at USD 96.95 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 61.44 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 45.83 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Cash and Eqv
Highest at USD 659.79 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -6.9% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Haemonetics Corp.
Interest
At USD 8.12 MM has Grown at 12.62%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Debtors Turnover Ratio
Lowest at 6.47 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio






